Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annu...(and its subsequent interaction with the ...)

Date:4/30/2009

and its subsequent interaction with the xenobiotic-response element (XRE) sequence on the CYP1A1 promoter region, causing induction of CYP1A1 transcription. This enzyme expression converts AF to metabolites that are covalently bound to DNA. This results in phosphorylation of p53 with induction of the p53 downstream target p21Waf1/Cip1 and apotosis.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

About the Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-look
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. Tigris Pharmaceuticals Files IND Application for GGTI-2418
3. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
4. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
7. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
8. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial